LONDON, Dec 14 (Reuters) – It is shaping up to be a bumper
year for drug approvals, with U.S. officials clearing twice as
many novel medicines as in 2016, yet returns on research
investment at leading pharmaceutical companies are down.

Read More At Article Source | Article Attribution